Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome

Histopathology

Volumn 56, Issue 3, 2010, Pages 331-344

  Barrow, Emma ^a   Jagger, Emma ^a   Brierley, Judith ^a   Wallace, Andrew ^b   Evans, Gareth ^c   Hill, James ^a   McMahon, Ray ^a,c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biological markers; DNA mismatch repair; Evaluation studies; Hereditary non polyposis colorectal cancer; Immunohistochemistry; Lynch syndrome

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING; SENSITIVITY AND SPECIFICITY; STAINING; TISSUE SECTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; AREA UNDER CURVE; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77449142136     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03485.x     Document Type: Article

References (40)

1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N. Engl. J. Med. 2003 348 919 932.
2. McKusick V. Online Mendelian inheritance in man. Bethesda, MD : National Center for Biotechnology Information, 2007.
3. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr. Opin. Genet. Dev. 1999 9 89 96.
4. Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 2006 354 2751 2763.
5. Salovaara R, Loukola A, Kristo P et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 2000 18 2193 2200. (Pubitemid 30350210)
6. Barrow E, McMahon R, Evans DG, Levine E, Hill J. Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer. Br. J. Surg. 2008 95 868 875.
7. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999 116 1453 1456.
8. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 2004 96 261 268. (Pubitemid 38256271)
9. Aaltonen LA, Peltomaki P, Mecklin JP et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994 54 1645 1648.
10. Wahlberg SS, Schmeits J, Thomas G et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002 62 3485 3492.
11. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 58 5248 5257.
12. Southey MC, Jenkins MA, Mead L et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J. Clin. Oncol. 2005 23 6524 6532.
13. Ward R, Meldrum C, Williams R et al. Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer. J. Cancer Res. Clin. Oncol. 2002 128 403 411.
14. Evans GD, Lalloo F, Mak T, Speake D, Hill J. Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes? J. Clin. Oncol. 2006 24 1960 1962 author reply 1962-1963.
15. Muller W, Burgart LJ, Krause-Paulus R et al. The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) - results of an international collaborative study. Fam. Cancer 2001 1 87 92.
16. Overbeek LI, Ligtenberg MJ, Willems RW et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am. J. Surg. Pathol. 2008 32 1246 1251.
17. Niessen RC, Berends MJ, Wu Y et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut 2006 55 1781 1788.
18. Shia J, Klimstra DS, Nafa K et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am. J. Surg. Pathol. 2005 29 96 104.
19. Christensen M, Katballe N, Wikman F et al. Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 2002 95 2422 2430.
20. Salahshor S, Koelble K, Rubio C, Lindblom A. Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab. Invest. 2001 81 535 541.
21. Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur. J. Cancer 2000 36 49 54.
22. Thibodeau SN, French AJ, Roche PC et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996 56 4836 4840.
23. Stormorken AT, Bowitz-Lothe IM, Noren T et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. J. Clin. Oncol. 2005 23 4705 4712.
24. Walker RA. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006 49 406 410.
25. McCarty KS Jr., Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 1985 109 716 721.
26. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999 17 1474 1481.
27. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 1995 48 876 878.
28. Manavis J, Gilham P, Davies R, Ruszkiewicz A. The immunohistochemical detection of mismatch repair gene proteins (MLH1, MSH2, MSH6, and PMS2): practical aspects in antigen retrieval and biotin blocking protocols. Appl. Immunohistochem. Mol. Morphol. 2003 11 73 77.
29. Hansen TP, Nielsen O, Fenger C. Optimization of antibodies for detection of the mismatch repair proteins MLH1, MSH2, MSH6, and PMS2 using a biotin-free visualization system. Appl. Immunohistochem. Mol. Morphol. 2006 14 115 121.
30. de Jong AE, van Puijenbroek M, Hendriks Y et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 2004 10 972 980.
31. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Fam. Cancer 2006 5 353 358.
32. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994 309 188.
33. Barnetson RA, Cartwright N, van Vliet A et al. Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum. Mutat. 2008 29 367 374.
34. Barratt PL, Seymour MT, Stenning SP et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002 360 1381 1391.
35. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003 349 247 257.
36. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005 23 609 618.
37. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998 95 6870 6875.
38. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998 58 3455 3460.
39. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am. J. Pathol. 2000 156 1773 1779.
40. Taylor CR, Levenson RM. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006 49 411 424.